Novolin Injection, Suspension
Product Images NDC 0169-1837

Product Visual Gallery

This gallery contains 34 technical images submitted to the FDA as part of the official labeling for Novolin (NDC 0169-1837). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk Pharmaceutical Industries, Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Novolin 70/30 Vial Carton (Image 01)

Chemical structure diagram showing the amino acid sequence and disulfide bonds of the human insulin A-chain and B-chain. The illustration highlights specific amino acids and the connectivity between cysteine residues forming disulfide bridges in the insulin molecule.*

FDA Label Image

Novolin 70/30 Relion Vial Carton (Image 02)

Packaging label for Novolin 70/30 injection, a 100 units/mL human insulin isophane suspension and human insulin injection. The label shows it is a 10 mL multi-dose vial, manufactured by Novo Nordisk Pharmaceutical Industries, LP. It includes usage instructions, warnings, contact information, and storage guidelines.*

FDA Label Image

Image 03

Box packaging label for Novolin 70/30 human insulin isophane suspension and human insulin injection, U-100 strength (100 units/mL), 10 mL multi-dose vial. The label includes usage instructions, storage conditions, warnings, and contact information. Labeler is Novo Nordisk Pharmaceutical Industries, LP, with exclusive retail sale through Walmart and affiliates under the ReliOn brand.*

FDA Label Image

Image 04

Novolin 70/30 FlexPen human insulin injection 100 units/mL carton label showing a 5-pack of 3 mL prefilled pens. The label includes dosage form as injection suspension for subcutaneous use, manufacturer Novo Nordisk Pharmaceutical Industries, LP, and usage instructions such as storage conditions and single patient use indication. The packaging features warnings, lot and expiration date fields, and Novolin 70/30 branding with orange and blue accents.*

FDA Label Image

Image 05

Packaging label for Novolin 70/30 FlexPen, a human insulin isophane suspension and human insulin injection, 100 units/mL (U-100), in a 5 x 3 mL prefilled pen package. Intended for subcutaneous use only by a single patient. Manufactured by Novo Nordisk Pharmaceutical Industries, LP, and labeled for retail sale by Walmart and its affiliates under the ReliOn brand. The label includes warnings, storage instructions, and usage recommendations.*

FDA Label Image

Image 12

Carton packaging for Novolin 70/30 Human Insulin Injection, Suspension, 100 IU/mL, a subcutaneous OTC drug. The box is predominantly white with blue and orange accents, displaying the Novo Nordisk logo and labeler name Novo Nordisk Pharmaceutical Industries, LP. The product name and type are prominently printed on the front panel.*

FDA Label Image

Image 13

An instructional illustration of the Novolin 70/30 FlexPen injection device, showing labeled parts including the pen cap, rubber stopper, 12 glass units ball, cartridge, cartridge scale, dose pointer selector, and push button. The image details the components of the pen used for subcutaneous administration of Human Insulin 100 IU/mL.*

FDA Label Image

Image 14

Illustration showing components of three types of pen needles: NovoFine, NovoFine Plus, and NovoTwist. Each set includes a big outer needle cap, an inner needle cap, the needle itself, and a protective tab arranged in sequence.*

FDA Label Image

Image 15

An instructional illustration showing a hand preparing a prefilled insulin pen for use. The image depicts twisting or unlocking motion of the pen cap, typical for devices like Novolin 70/30 human insulin injection pens used for subcutaneous administration.*

FDA Label Image

Image 16

An instructional illustration showing two sequential steps involving hand and arm movements. The first step depicts a hand holding an object upright with the thumb and forefinger. The second step shows the arm extended horizontally holding the same object, indicating a motion or procedural use related to the product Novolin 70/30 injection.*

FDA Label Image

Image 17

Novolin 70/30 Human Insulin 100 IU/mL injection suspension label, displaying a vial with a multicolor label showing product name, concentration, and manufacturer Novo Nordisk Pharmaceutical Industries, LP. The label includes visual elements such as color bands and dosage information intended for subcutaneous use.*

FDA Label Image

Image 18

Instructional illustration showing hands preparing a NovoFine or NovoFine Plus needle and a NovoTwist needle for injection. The diagram demonstrates the correct attachment or removal technique with arrows indicating hand movements.*

FDA Label Image

Image 19

An instructional illustration showing the connection method for Novofine and NovoTwist needles. The image uses arrows to indicate the proper attachment of the needles to the syringe or pen device, emphasizing the different connection styles of each needle type.*

FDA Label Image

Image 20

An instructional illustration showing the use of Novofine and Novotwist injection needles or devices. The diagram depicts hands connecting or handling components, demonstrating the proper assembly or usage technique for subcutaneous injections, likely related to Novolin 70/30 Human Insulin injection.*

FDA Label Image

Image 21

An instructional illustration showing a hand adjusting a dose selector on a pen injector for Novolin 70/30 insulin. The dose window displays '2 units selected,' demonstrating how to set the insulin dose before injection.*

FDA Label Image

Image 22

An instructional illustration showing a hand tapping or shaking a prefilled syringe of Novolin 70/30 human insulin injection suspension before subcutaneous administration. The image emphasizes preparation of the insulin syringe prior to injection.*

FDA Label Image

Image 23

An instructional diagram illustrating a hand holding a Novolin 70/30 injection pen, preparing it for use. The image shows the removal of the cap with an upward arrow and includes a close-up inset highlighting the pen needle attachment area.*

FDA Label Image

Image 24

Novolin 70/30 Human Insulin injection, suspension 100 IU/mL vial from Novo Nordisk Pharmaceutical Industries, LP. The label includes dosage strength, product and manufacturer information on a white background with orange and gray accents, designed for subcutaneous use.*

FDA Label Image

Image 25

Novolin 70/30 Human Insulin injection, suspension, 100 [iU]/mL in a vial. The label shows the brand name Novolin 70/30 prominently with the strength 100 units/mL, indicating it is for subcutaneous use. The vial is clear glass with a purple and white color scheme on the label and the Novo Nordisk logo.*

FDA Label Image

Image 26

Novolin 70/30 Human Insulin Injection, Suspension label showing a clear vial with yellow cap. The vial contains 100 units/mL concentration of insulin for subcutaneous use. The label includes product name Novolin 70/30 with active ingredient Human Insulin. The labeler is Novo Nordisk Pharmaceutical Industries, LP, with an NDC barcode visible.*

FDA Label Image

Image 27

An instructional illustration showing a close-up of a dosing window on a pen injector device for Novolin 70/30 human insulin injection. The image highlights how to select insulin units by turning a dial, with two examples displayed: 5 units and 24 units selected.*

FDA Label Image

Image 28

Novolin 70/30 human insulin 100 IU/mL suspension injection vial with a white label featuring blue and red text. The label includes dosing information and product identification for subcutaneous use. The vial is the typical small glass type used for injectable medication, labeled by Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

Image 29

An instructional illustration showing a hand pressing down on the cap of a Novolin 70/30 insulin vial, with an inset detail indicating a magnified view of the vial cap's mechanism for opening. This diagram is related to the preparation or use of the human insulin injection suspension.*

FDA Label Image

Image 30

An illustration showing the tip of a syringe with a needle, positioned for injection onto a flat surface, likely demonstrating the subcutaneous injection technique for a liquid suspension medication.*

FDA Label Image

Image 31

Instructional illustration showing how to prepare or use a syringe with a needle cap being removed. A hand is pulling back the needle cap to expose the needle, indicating the syringe is ready for injection use.*

FDA Label Image

Image 32

Novolin 70/30 Human Insulin Injection, Suspension carton and vial label showing 100 IU/mL strength. The product is intended for subcutaneous use and labeled by Novo Nordisk Pharmaceutical Industries, LP. Packaging includes a carton and a vial with printed product information.*

FDA Label Image

Image 33

Novolin 70/30 Human Insulin injection, suspension, 100 IU/mL, in a 10 mL vial. The label shows the product name, concentration, and vial size, with dosing and storage information partially visible. Manufactured by Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

Image 34

Novolin 70/30 Human Insulin Injection, Suspension, 100 IU/mL in a 10 mL vial. The label shows the product name, concentration, dosage form, and the labeler Novo Nordisk Pharmaceutical Industries, LP. The vial is designed for subcutaneous administration.*

FDA Label Image

Image 35

Novolin 70/30 Human Insulin 100 IU/mL Injection, Suspension packaging label. The carton shows the brand name Novolin 70/30 prominently, indicating a combination insulin product. The label includes detailed dosage information and instructions, with Novo Nordisk Pharmaceutical Industries, LP as the manufacturer. The packaging is primarily white with some orange and blue text and design elements.*

FDA Label Image

Image 36

Novolin 70/30 Human Insulin 100 IU/mL injection suspension label from Novo Nordisk Pharmaceutical Industries, LP. The vial label shows the proprietary name, insulin type, concentration, and usage route, with branding and regulatory information.*

FDA Label Image

Image 37

Novolin 70/30 human insulin 100 IU/mL injection suspension vial label. The label includes the proprietary name Novolin 70/30, the dosage form as injection suspension, and indicates subcutaneous use. The labeler is Novo Nordisk Pharmaceutical Industries, LP. The vial contains 100 IU/mL strength insulin suspension.*

FDA Label Image

Image 38

Novolin 70/30 Human Insulin Injection, Suspension, 100 IU/mL, in a panel showing the proprietary and generic names, dosage form, strength, and labeler Novo Nordisk Pharmaceutical Industries, LP. The label is primarily white with blue and red elements and includes usage instructions and ingredient information.*

FDA Label Image

Image 39

Novolin 70/30 Human Insulin injection, suspension, 100 iU/mL vial label. The label includes dosage form, concentration, and manufacturer Novo Nordisk Pharmaceutical Industries, LP. The vial shows standard medical information in blue, green, and white colors.*

FDA Label Image

Image 40

Novolin 70/30 Human Insulin injection, suspension, 100 IU/mL, in a 10 mL vial with a blue cap. The label shows the Novo Nordisk Pharmaceutical Industries, LP logo and includes dosing, storage, and handling details typical for this product.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.